LSE - Delayed Quote USD
BioNTech SE (0A3M.L)
166.47
0.00
(0.00%)
As of July 21 at 7:14:04 PM GMT+1. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in EUR | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 20 | 20 |
| Avg. Estimate | 144.66M | 705.89M | 2.03B | 2.21B |
| Low Estimate | 82.26M | 486M | 1.7B | 1.42B |
| High Estimate | 406.4M | 1.01B | 2.73B | 3.54B |
| Year Ago Sales | 128.7M | 1.24B | 2.75B | 2.03B |
| Sales Growth (year/est) | 12.40% | -43.29% | -26.30% | 8.76% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 0A3M.L | -- | -- | -- | -- |
| S&P 500 | 13.30% | 2.58% | 7.71% | 13.75% |
Upgrades & Downgrades
| Maintains | JP Morgan: Neutral to Neutral | 5/22/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/22/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/14/2025 |
| Maintains | Citigroup: Buy to Buy | 5/6/2025 |
| Maintains | Morgan Stanley: Overweight to Overweight | 5/6/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/1/2025 |